Mucositis Therapeutics| A Pipeline Analysis Report 2018| Technavio

LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio has announced their latest pipeline analysis report on the mucositis
therapeutics market
. The report includes a detailed analysis of
the pipeline molecules under investigation within the defined data
collection period to treat mucositis therapeutics.


This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Mucositis therapeutics: Market overview

Mucositis refers to the inflammation of the mucous membranes, which is
generally due to the side effects of cancer radiotherapy and
chemotherapy. Mucositis is painful, and it occurs in the
gastrointestinal tract. The mucosal tissue, which is also known as
mucosa or the mucous membrane, is the most sensitive tissue in the human
body, and the cancer treatment leaves it open, which tends to build up
the infection, and the mucosal tissue starts getting inflamed.

According to a senior market research analyst at Technavio, “Oral
mucositis is when the inflammation and the ulceration occur in the mouth
while it can spread across the whole gastrointestinal tract, adversely
affecting the digestive system. The degree of mucositis depends upon the
severity. However, high-dose radiotherapy and chemotherapy are the major
causes of severe mucositis.”

Mucositis therapeutics: Segmentation analysis

This pipeline analysis report segments the mucositis therapeutics market
based on therapies employed (monotherapy and combination therapy), RoA
(oral, intravenous, and oral+intravenous), therapeutic modality (small
molecule, peptide and plant derived), targets (CB2 and TRPV1, CD47-SIRP
a checkpoint, DHFR, HDP, mucoprotein, prostaglandin, SQSTMT, superoxide
dismutase, a2AR, uridine phosphorylase, malondialdehyde, and
neutrophil), MoA (CB2 and TRPV1 antagonist, CD47-SIRP a checkpoint
inhibitor, DHFR inhibitor, HDP mimic, mucoprotein stimulants,
prostaglandin agonists, SQSTMT inhibitor, superoxide dismutase
modulator, a2AR agonist, uridine phosphorylase inhibitors,
malondialdehyde inhibitors, and neutrophil stimulants), geographical
segmentation (US, Puerto Rico, Asia, Canada, and Europe) and recruitment
status (active, not recruiting, completed, not yet recruiting, and
recruiting). It provides an in-depth analysis of the prominent factors
influencing the market, including drivers, opportunities, trends, and
industry-specific challenges.

Around 40% of the molecules that are being investigated for the
treatment of mucositis are small molecule.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Hypogonadism | A Pipeline Analysis Report 2018 | Technavio

LONDON–(BUSINESS WIRE)–#Healthcare–Technavio has announced their latest pipeline analysis report on the hypogonadism
market
. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat hypogonadism.


This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Hypogonadism: Market overview

When there is less or no secretion of the sex hormones, it leads to
various changes in the secondary sexual characteristics. This condition
is termed as hypogonadism. Secondary sexual characteristics include
breast development in females and testicular development in males.
Therefore, the production of sex hormones affects the menstrual cycle
and sperm production. The glands that produce the sex hormones are known
as gonads. Hence, hypogonadism is also termed as gonad deficiency.

According to a senior market research analyst at Technavio, “Hypogonadism
is largely seen in middle-aged and older-aged individuals. The incidence
of hypogonadism increases with age. There is an increase in the number
of people aged 65 years and above in the US. This rise in number of
people belonging to the higher age group may lead to an increase in the
incidences of hypogonadism. As a result, the increasing incidences of
hypogonadism is expected to boost the drug development for hypogonadism.”

Hypogonadism: Segmentation analysis

This pipeline analysis report segments the hypogonadism market based on
therapies employed (monotherapy and combination therapy), RoA (oral,
nasal, subcutaneous, topical, and transdermal), therapeutic modality
(small molecule, fusion protein and peptide), targets (androgen
receptor, androgen+estrogen receptor, estrogen receptor, and
follicle-stimulating hormone receptor), MoA (androgen receptor agonist,
androgen+estrogen receptor agonist, estrogen receptor
antagonist/agonist, and follicle-stimulating hormone receptor),
geographical segmentation (US, Canada, and Europe) and recruitment
status (active, not recruiting, completed, not yet recruiting, and
recruiting). It provides an in-depth analysis of the prominent factors
influencing the market, including drivers, opportunities, trends, and
industry-specific challenges.

Around 67% of the molecules that are being investigated for the
treatment of hypogonadism are androgen receptor agonists.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)

NIVESTYM™, a biosimilar to Neupogen®
(filgrastim), is Pfizer’s fourth biosimilar to be approved by the FDA

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.)
Food and Drug Administration (FDA) has approved NIVESTYM™
(filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim),
for all eligible indications of the reference product.

“The FDA approval of NIVESTYM marks an important step in helping expand
access to critical treatment options for patients with neutropenia, many
of whom have cancer and can be hospitalized for potentially
life-threatening side effects stemming from chemotherapy,” said Berk
Gurdogan, U.S. Institutions President, Pfizer Essential Health. “We
believe biosimilars, like NIVESTYM, are essential in helping to address
evolving healthcare needs and may provide more affordable medicines to
patients.”

The FDA approval was based on a review of a comprehensive data package
and totality of evidence demonstrating a high degree of similarity of
NIVESTYM compared to its reference product.

In the U.S., NIVESTYM is indicated:2

  • To decrease the incidence of infection, as manifested by febrile
    neutropenia, in patients with nonmyeloid malignancies receiving
    myelosuppressive anti-cancer drugs associated with a significant
    incidence of severe neutropenia with fever.
  • For reducing the time to neutrophil recovery and the duration of
    fever, following induction or consolidation chemotherapy treatment of
    patients with acute myeloid leukemia (AML).
  • To reduce the duration of neutropenia and neutropenia-related clinical
    sequelae, e.g., febrile neutropenia, in patients with nonmyeloid
    malignancies undergoing myeloablative chemotherapy followed by bone
    marrow transplantation (BMT).
  • For the mobilization of autologous hematopoietic progenitor cells into
    the peripheral blood for collection by leukapheresis.
  • For chronic administration to reduce the incidence and duration of
    sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal
    ulcers) in symptomatic patients with congenital neutropenia, cyclic
    neutropenia, or idiopathic neutropenia.

NIVESTYM is expected to be available in the U.S. at a significant
discount to the current wholesale acquisition cost (WAC) of Neupogen.
WAC is not inclusive of discounts to payers, providers, distributors and
other purchasing organizations.

NIVESTYM is Pfizer’s fourth biosimilar to be approved by the U.S. FDA.
Pfizer’s biosimilars pipeline consists of 10 distinct biosimilar
molecules with five assets in mid-to-late stage clinical development.3

NIVESTYM™ IMPORTANT SAFETY INFORMATION

Do not take NIVESTYM if you have had a serious
allergic reaction to human G-CSFs such as filgrastim or pegfilgrastim
products.

Before you take NIVESTYM, tell your healthcare provider all about
your medical conditions, including if you:

  • have a sickle cell disorder
  • have kidney problems
  • are receiving radiation therapy
  • are pregnant or plan to become pregnant. It is not known if NIVESTYMwill harm your unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if NIVESTYMpasses into your breast milk

Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins, and
herbal supplements.

How will I receive NIVESTYM?

  • NIVESTYMinjections can be given by a healthcare provider
    by intravenous (IV) infusion or under your skin (subcutaneous
    injection). Your healthcare provider may decide that subcutaneous
    injections can be given at home by you or your caregiver. If NIVESTYMis given at home, see the detailed “Instructions for Use” that
    comes with your NIVESTYMprescription for information on
    how to prepare and inject a dose of NIVESTYM.
  • You and your caregiver should be shown how to prepare and inject
    NIVESTYM, before you use it, by your healthcare provider.
  • Your healthcare provider will tell you how much NIVESTYMto
    inject and when to inject it. Do not change your dose or stop NIVESTYMunless your healthcare provider tells you to.
  • If you are receiving NIVESTYMbecause you are also
    receiving chemotherapy, your dose of NIVESTYMshould be
    injected at least 24 hours before or 24 hours after your dose of
    chemotherapy.
  • If you miss a dose of NIVESTYM, talk to your healthcare provider about
    when you should give your next dose.

What are the most common side effects of NIVESTYM?

  • The most common side effects of NIVESTYM include aching in the bones
    and muscles.

What are possible side effects of NIVESTYM?

NIVESTYM may cause serious side effects including:

  • Spleen rupture. Your spleen may become enlarged and can
    rupture. A ruptured spleen can cause death.
  • Acute Respiratory Distress Syndrome (ARDS). ARDS is a serious
    lung problem.
  • Serious allergic reactions. These can occur anywhere in your
    body. If you have an allergic reaction, stop using NIVESTYM.
  • Sickle cell crises. Serious sickle cell crises have happened in
    people with sickle cell disorders receiving NIVESTYM that have
    sometimes led to death.
  • Kidney injury (glomerulonephritis). NIVESTYM can cause kidney
    injury.
  • Capillary Leak Syndrome. NIVESTYM can cause fluid to leak from
    blood vessels into your body’s tissues. This condition is called
    “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have
    symptoms that may become life-threatening.
  • Decreased platelet count (thrombocytopenia). Your healthcare
    provider will check your blood during treatment with NIVESTYM. Tell
    your healthcare provider if you have unusual bleeding or bruising
    during treatment with NIVESTYM. This could be a sign of decreased
    platelet counts, which may reduce the ability of your blood to clot.
  • Increased white blood cell count (leukocytosis). Your
    healthcare provider will check your blood during treatment with
    NIVESTYM.
  • Inflammation of your blood vessels (cutaneous vasculitis). Tell
    your healthcare provider if you develop purple spots or redness of
    your skin.

Call your healthcare provider or seek emergency medical help right
away if you have:

  • pain in the left upper stomach area or left shoulder
  • symptoms of sickle cell crisis such as pain or trouble breathing
  • shortness of breath, with or without a fever, any trouble breathing,
    wheezing or a fast rate of breathing
  • a rash over your whole body, swelling around your mouth or eyes, fast
    heart rate and sweating
  • swelling or puffiness, especially swelling of your stomach-area and
    feeling of fullness
  • swelling of your face and ankles
  • blood in your urine or dark colored urine
  • less than usual urination
  • dizziness or are feeling faint
  • a general feeling of tiredness

These are not all the possible side effects of NIVESTYM. Call your
healthcare provider for medical advice about side effects.

You are encouraged to report adverse events related to Pfizer products
by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact
the U.S. Food and Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatch
or call 1-800-FDA-1088.

Please see full Prescribing
Information
and Patient Information for NIVESTYM (filgrastim-aafi).

Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer
and @Pfizer_News,
LinkedIn,
YouTube
and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of
July 20, 2018. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new information or
future events or developments.

This release contains forward-looking information about NIVESTYM™
(filgrastim-aafi), including its potential benefits, that involves
substantial risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, uncertainties
regarding the launch timing and commercial success of NIVESTYM in the
United States; the uncertainties inherent in research and development;
whether and when any applications for NIVESTYM may be filed with
regulatory authorities in any other jurisdictions; whether and when
regulatory authorities in any other jurisdictions may approve any such
other applications that are pending or that may be filed for NIVESTYM,
which will depend on the assessment by such regulatory authorities of
the benefit-risk profile suggested by the totality of the efficacy and
safety information submitted and, if approved, whether NIVESTYM will be
commercially successful; intellectual property and/or litigation
implications; decisions by regulatory authorities regarding labeling and
other matters that could affect the availability or commercial potential
of NIVESTYM; uncertainties regarding access challenges for our
biosimilar products where our product may not receive access at parity
to the innovator product and remains in a disadvantaged position; and
competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2017, including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 10-Q and Form
8-K, all of which are filed with the U.S. Securities and Exchange
Commission and available at
www.sec.gov
and
www.pfizer.com.

1 Neupogen® is a registered trademark of Amgen Inc.
2
Nivestym™ (filgrastim-aafi) Prescribing Information. New York. NY:
Pfizer Inc: 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761080s000lbl.pdf?utm_campaign=FDA%20approves%20Nivestym%20%28filgrastim-aafi%29%20a%20biosimilar%20to%20Neupogen%20%28filgrastim%29&utm_medium=email&utm_source=Eloqua.
3
Pfizer. (2018, January 30). Pfizer pipeline. Retrieved from https://www.pfizer.com/sites/default/files/product-pipeline/01302018_PipelineUpdate.pdf.

Contacts

Pfizer Inc.
Media:
Thomas Biegi, +1 212-733-2204
Thomas.Biegi@pfizer.com
or
Investors:
Ryan
Crowe, +1 212-733-8160
Ryan.Crowe@pfizer.com

UnitedHealthcare and Optum Take Action to Support People Affected by Tornadoes in Central Iowa

  • Assistance for UnitedHealthcare plan participants whose access
    to care or prescriptions needs may have been affected
  • Free emotional-support help line from Optum open to anyone

DES MOINES, Iowa–(BUSINESS WIRE)–UnitedHealthcare and Optum, the health benefits and services companies
of UnitedHealth Group (NYSE: UNH), are taking action to help people
affected by the recent tornadoes that swept through parts of central
Iowa.

Support includes assisting health plan participants who may need to make
alternate arrangements to access care and early prescription refills, as
well as offering a free emotional-support line to help people who might
be affected.

  • Help Finding a Network Care Provider, Early Refills: Plan
    participants who need help finding a care provider in the
    UnitedHealthcare network or obtaining early prescription refills can
    call customer care at the number located on the back of their medical
    ID cards.
  • For plan participants who may have misplaced their medical ID
    cards,
    call 866-633-2446, 8 a.m.-8 p.m. (in the local time zone),
    Monday through Friday. People enrolled in Medicaid, employer-sponsored
    and individual health plans (except Medicare) who have a smartphone
    can download the free Health4Me app, which provides instant
    access to their ID card, network care providers, their personal health
    benefits and more. The Health4Me app is available as a free download
    at the Apple iTunes
    App Store
    and the Android Market on Google
    Play
    .
  • Free Help Line: Optum, a leading health and behavioral health
    services company, is offering a free emotional-support help line.

    The
    toll-free number, 866-342-6892, will be open 24 hours a day, seven
    days a week, for as long as necessary. The service is free of charge
    and open to anyone. Specially trained Optum mental health specialists
    help people manage their stress and anxiety so they can continue to
    address their everyday needs. Callers may also receive referrals to
    community resources to help them with specific concerns, including
    financial and legal matters.

    Along with the toll-free help
    line, emotional-support resources and information are available online
    at www.liveandworkwell.com.

About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a
diversified health and well-being company dedicated to helping people
live healthier lives and helping to make the health system work better
for everyone. UnitedHealth Group offers a broad spectrum of products and
services through two distinct platforms: UnitedHealthcare, which
provides health care coverage and benefits services; and Optum, which
provides information and technology-enabled health services. For more
information, visit UnitedHealth Group at www.unitedhealthgroup.com
or follow @UnitedHealthGrp on Twitter.

Click
here to subscribe to Mobile Alerts for UnitedHealth Group
.

Contacts

UnitedHealth Group
Dimitri Senaratna, 952-936-3275
dimitri_senaratna@uhg.com

$17 Billion HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “HIV
Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2018-2023”
report has been added to ResearchAndMarkets.com’s
offering.

The global HIV drugs market exceeded a value of US$ 17 Billion in 2017.

One of the primary factors catalyzing the growth of the global HIV drugs
market is increase in the prevalence of HIV and its diagnosis. Apart
from this, the market is also influenced by a rise in the number of
government initiatives for spreading the awareness amongst people
regarding causes, symptoms and treatments.

Moreover, the introduction of generic drugs, which are cost-effective
and chemically identical to branded drugs, act as another factor that is
contributing towards the demand for HIV drugs.

Looking forward, the market value is projected to reach approximately
US$ 21 Billion by 2023, expanding at a CAGR of more than 3% during
2018-2023.

Market Summary:

  • Based on class, the market has been segmented into multi-class
    combination products, nucleoside reverse transcriptase inhibitors,
    non-nucleoside reverse transcriptase inhibitors, protease inhibitors,
    fusion inhibitors, entry inhibitors – CCR5 co-receptor antagonist and
    HIV integrase strand transfer inhibitors.
  • On the basis of distribution channel, the market is segregated as
    hospital pharmacies, retail pharmacies, online pharmacies and others.
    Hospital pharmacies currently account for the largest share.

The competitive landscape of the market has also been examined
with some of the key players being

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global HIV Drugs Market

6 Market Breakup by Drug Class

7 Market Breakup by Distribution Channel

8 Market Breakup by Region

9 HIV Drugs Manufacturing Process

10 Competitive Landscape

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Merck & Co.
  • Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan

For more information about this report visit https://www.researchandmarkets.com/research/7hlwwj/17_billion_hiv?w=4

Did you know that we also offer Custom Research? Visit our Custom
Research
page to learn more and schedule a meeting with our Custom
Research Manager.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs
, Infectious
Diseases Drugs
, HIV/AIDS
Drugs

Retinitis Pigmentosa | A Pipeline Analysis Report 2018 | Technavio

LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio has announced their latest pipeline analysis report on the retinitis
pigmentosa market
. The report includes a detailed analysis of
the pipeline molecules under investigation within the defined data
collection period to treat retinitis pigmentosa.


This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Retinitis pigmentosa: Market overview

Retinitis pigmentosa is a genetic disorder that results in vision loss.
It is known to progress over a period and results in complete blindness.
Retinitis pigmentosa is caused by mutations in one of over 100 types of
genes. The breakdown and loss of cells in the retina are also known to
cause retinitis pigmentosa. Retinitis pigmentosa can broadly be
classified into three categories, namely nonsyndromic, syndromic, and
secondary. Nonsyndromic is when the disease occurs alone and does not
affect any other sensory organs. Syndromic occurs when retinitis
pigmentosa occurs with other neurosensory disorders or developmental
abnormalities. Secondary occurs because of other systemic diseases.

According to a senior market research analyst at Technavio, “Retinitis
pigmentosa is one of the most common types of inherited retinal
disorders. The prevalence of the disorder is higher in children and
young adults compared to the older population. Patients with retinitis
pigmentosa generally inherit this disease from their parents. The onset
is often in childhood. However, in some cases, the disease does not
begin until adulthood. The type and speed of vision loss caused by
retinitis pigmentosa differ from person to person and factors, such as
the form of the condition.”

Retinitis pigmentosa: Segmentation analysis

This pipeline analysis report segments the retinitis pigmentosa market
based on therapies employed (monotherapy), RoA (subretinal,
intravitreal, implant, intraocular, and topical), therapeutic modality
(gene, stem cell, protein and recombinant fusion protein), targets
(RPGR, RPE65, and RLBP1), MoA (gene therapy, stem cell therapy,
apoptosis inhibitors, VEGF inhibitor, Nerve growth factor receptor
agonists, and cellular growth stimulator), geographical segmentation
(US, UK, and France) and recruitment status (recruiting, active,not
recruiting, not yet recruiting, and completed). It provides an in-depth
analysis of the prominent factors influencing the market, including
drivers, opportunities, trends, and industry-specific challenges.

Around 61% of the molecules that are being investigated for the
treatment of retinitis pigmentosa are gene therapy.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Polycystic Ovary Syndrome | A Pipeline Analysis Report 2018 | Technavio

LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio has announced their latest pipeline analysis report on the polycystic
ovary syndrome market
. The report includes a detailed analysis
of the pipeline molecules under investigation within the defined data
collection period to treat polycystic ovary syndrome.


This report by Technavio presents a detailed analysis of the market,
including regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Polycystic ovary syndrome: Market overview

Polycystic ovary syndrome (PCOS) is a hormonal condition, which occurs
when a woman’s ovaries or adrenal glands produce more male hormones than
normal. PCOS is a common heterogeneous endocrine disorder characterized
by irregular menses, hyperandrogenism, and polycystic ovaries. It
develops cysts (fluid filled sacs) on the ovaries. It is also known as
Stein-Leventhal syndrome. It is one of the most common hormonal
endocrine disorders. PCOS is linked to the development of other medical
conditions such as insulin resistance, type 2 diabetes, high
cholesterol, high blood pressure, and heart disease.

According to a senior market research analyst at Technavio, “Polycystic
ovary syndrome is the most common cause of female infertility, affecting
6% to 12% of the US women of reproductive age. PCOS is a lifelong health
condition that continues far beyond the child-bearing years.”

Polycystic ovary syndrome: Segmentation analysis

This pipeline analysis report segments the polycystic ovary syndrome
market based on therapies employed (monotherapy, combination therapy,
and monotherapy/combination therapy), RoA (oral), therapeutic modality
(small molecule, and biological), targets (kisspeptin receptor, AMPK,
neurokinin 3 receptor, and others), MoA (kisspeptin receptor antagonist,
neurokinin 3 receptor antagonist, AMPK activator, and others ),
geographical segmentation (US, Germany, and Belgium) and recruitment
status (recruiting, active, not recruiting, and completed). It provides
an in-depth analysis of the prominent factors influencing the market,
including drivers, opportunities, trends, and industry-specific
challenges.

Almost 89% of the molecules that are being investigated for the
treatment of polycystic ovary syndrome are small molecule.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Good Neighbor Pharmacy Evolves Offerings to Strengthen the Future of Independent Community Pharmacy

At ThoughtSpot 2018, leaders announce program enhancements that will
help pharmacists thrive today and in the future

ORLANDO, Fla.–(BUSINESS WIRE)–Today, AmerisourceBergen and Good Neighbor Pharmacy announced new
and enhanced programs that will help independent pharmacies strengthen
the core of their businesses and expand their role within their
communities. The programs and solutions, which were presented at
ThoughtSpot 2018, Good Neighbor Pharmacy’s annual tradeshow,
reflect AmerisourceBergen and Good Neighbor Pharmacy’s continued
commitment to supporting independent pharmacies today and in the future.

“We firmly believe that this is an incredible time to be an independent
community pharmacy,” said Brian Nightengale, RPh, Ph.D., president of Good
Neighbor Pharmacy
and SVP, Community & Specialty Pharmacy,
AmerisourceBergen. “Our belief stems from what we see in communities
nationwide and in changing consumer demands and demographics. Whether it
is expanding their role to meet growing primary care needs or improving
population health through drug therapy management, independent
pharmacies continue to deliver significant value. We are confident that
their role will continue to grow and that their value will be
increasingly recognized, which is why we continue to increase our
investments and augment our programs.”

During ThoughtSpot’s general session, Good Neighbor Pharmacy
leaders unveiled how the company is evolving its solutions into a
simple, tiered program structure. The streamlined approach, which was
informed by member perspectives, makes it easier for customers to access
and navigate programs and solutions. Good Neighbor Pharmacy
programs are now organized within four value centers: In-store
Experience, Marketing, Managed Care and Business Performance. The
collective suite of solutions helps pharmacies simplify their business
operations, amplify their brand and protect their independence and
profitability.

AmerisourceBergen leaders also highlighted how the company is investing
time, energy and resources to advocate for new, value-based payment
models that are based on quality and outcomes resulting from the care
pharmacists provide beyond dispensing. Part of that is driving awareness
of pharmacy participation in and network adequacy for Community Pharmacy
Enhanced Services Networks (CPESN). During general session, Nightengale
announced that AmerisourceBergen is partnering with CPESN®
Tennessee and the Tennessee Pharmacists Research and Education
Foundation, a direct subsidiary of the Tennessee Pharmacists
Association, to launch a readiness program that allows for 70 CPESN®
Tennessee participating pharmacies to provide Congestive Heart Failure
(CHF) interventions. The readiness program, which kicks off August 1, is
designed to test and validate a scalable roadmap for pharmacists, payers
and other providers to engage in a consistent model of community
pharmacist-provided services for CHF.

General session also featured perspectives from retail consultant
Michael Dart, who delivered the keynote speech on trends shaping
consumer beliefs, as well as U.S. Rep. Doug Collins (R-GA) on the
actions independent community pharmacists can take to elevate their
voice on legislation impacting their ability to provide care.

Following general session, AmerisourceBergen and Good Neighbor
Pharmacy
hosted “Women in Pharmacy,” a seven-member panel of
high-performing pharmacists, pharmacy leaders and executives. Together,
the diverse panel members shared stories about how their roles evolved
over the course of their careers and revealed the challenges and
opportunities they encountered while learning to balance life,
leadership and the demands of a complex business.

AmerisourceBergen also recognized Shatto’s Frontier Drug from Douglas,
Wyoming, and co-owners Gary and Jan Shatto as the recipient of Good
Neighbor Pharmacy’s
2018 Pharmacy of the Year Award. The pharmacy,
which emerged from a field of nearly 60 nominees, received the esteemed
award for exemplifying what it means to be a Good Neighbor Pharmacy in
their commitment to enhancing patient care and lives in local
communities. Shatto’s Frontier Drug has been a staple in its community
for more than 40 years. As part of the pharmacy’s patient-centered
approach, pharmacists work to ensure patients have the medications they
need, when they need them – even if it means driving 60 miles to pick up
a medication they do not have on their shelves.

ThoughtSpot is an annual conference hosted by Good Neighbor Pharmacy, a
national independent pharmacy network offered through AmerisourceBergen.
It aims to equip independent pharmacists with practices and resources
they can use to transform their businesses to improve profitability and
maintain their position as a vital source of patient care in their local
communities. For more information on the ThoughtSpot conference, please
visit: www.thoughtspot2018.com.

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
21,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500,
with more than $150 billion in annual revenue. The company is
headquartered in Valley Forge, Pennsylvania, and has a presence in 50+
countries. Learn more at amerisourcebergen.com.

Contacts

AmerisourceBergen
Francesca Gunning
215-603-9264– Cell Phone
fgunning@amerisourcebergen.com
or
Tierney
Communications
Mike Iorfino
551-427-8194– Cell Phone
miorfino@tierneyagency.com

Koutif Therapeutics Confirms Clinical Candidate Drug

Company Expects to File IND Application in Late 2018

CLEVELAND & PITTSBURGH–(BUSINESS WIRE)–#BioMotiv–Koutif Therapeutics today announced that KT-1002, which has been
selected as its lead compound, has reached clinical candidate status for
the treatment of inflammatory bowel disease, including ulcerative
colitis and Crohn’s Disease, after successfully completing IND-enabling
studies. The biotech start-up’s small molecule oral inhibitor of Fbxo3,
an E3 ligase, also shows promise in the treatment of multiple
inflammatory condition targets, including bronchiolitis obliterans
syndrome, chronic obstructive pulmonary disease, acute lung injury, and
rheumatoid arthritis.

“We are very encouraged by the results of the lead compound both in
IND-enabling studies as well as in disease models,” said Baiju R. Shah,
CEO of BioMotiv and Chairman of Koutif Therapeutics. “Based on the data,
we plan to file an IND application by the end of the year.”

Koutif Therapeutics has exclusively licensed intellectual property,
which includes the lead compound KT-1002, from the University of
Pittsburgh and the United States Department of Veterans Affairs. KT-1002
was developed by Rama K. Mallampalli, MD, Professor and Chief of the
Pulmonary, Allergy and Critical Care Division at the University of
Pittsburgh School of Medicine and Staff Physician at the VA Pittsburgh
Healthcare System, and Beibei Chen, PhD, Associate Professor of
Medicine, Director, Small Molecule Therapeutic Center, Co-director,
Acute Lung Injury Center of Excellence at the University of Pittsburgh
School of Medicine, each of whom hold equity in Koutif Therapeutics and
serve as paid consultants to the company.

The intellectual property licensed from Pitt includes several compounds
that potently inhibit the novel target Fbxo3. KT-1002 causes degradation
of several potent, pro-inflammatory proteins, including multiple
proteins involved in adaptive and innate signaling pathways. This novel
mechanism has the potential to treat numerous inflammatory conditions.

The intellectual property derived from research funded by multiple
Department of Veterans Affairs Merit Awards and NIH grants, including
the prestigious NIH CADET grant awarded to Dr. Mallampalli in 2014. Dr.
Mallampalli has also received support from Harrington Discovery
Institute, which is supported in part by a grant from the Ohio Third
Frontier, as a 2016 Harrington Scholar-Innovator.

Click here
to learn more about Koutif Therapeutics.

About BioMotiv

BioMotiv is the mission-driven accelerator associated with The
Harrington Project for Discovery & Development, a $340 million
initiative for advancing medicine centered at University Hospitals in
Cleveland. The focus is to accelerate breakthrough discoveries from
research institutions into therapeutics for patients through an
innovative model that efficiently aligns capital and collaborations. The
company leverages an experienced team and advisory board to select,
fund, and actively manage and advance a portfolio of drug development
programs.

For more information, go to: www.biomotiv.com.

About The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington
Project) is a $340 million national initiative built to bridge the
translational valley of death. It includes the Harrington Discovery
Institute at University Hospitals in Cleveland and BioMotiv, a
for-profit, mission-aligned drug development company that accelerates
early discoveries into medicines for benefit of society.

For more information about The Harrington Project and the Harrington
Discovery Institute, visit: www.HarringtonDiscovery.org.

About University of Pittsburgh

The University of Pittsburgh is one of the nation’s leading research
universities with expertise across a broad range of academic
disciplines. The University seeks to achieve positive societal impact
through the commercial licensing of innovations developed from sponsored
research. To learn more about Pitt innovations available for licensing
visit www.innovation.pitt.edu,
or contact the Innovation Institute at innovate@pitt.edu.

Contacts

BioMotiv
Erin Reese, 216-508-1985
ereese@biomotiv.com

Behcet’s Syndrome | A Pipeline Analysis Report 2018 | Technavio

LONDON–(BUSINESS WIRE)–#Behcetssyndrome–Technavio has announced their latest pipeline analysis report on the Behcet’s
syndrome market
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat Behcet’s syndrome.


This report by Technavio presents a detailed analysis of the market,
including regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Behcet’s syndrome: Market overview

Behcet’s syndrome or Behcet’s disease is a rare type of autoimmune
disorder that results in inflammation of blood vessels throughout the
body. It affects multiple body parts. The complications caused due to
Behcet’s syndrome depends on the site of the body parts and symptoms.
For instance, untreated uveitis, the inflammation of the middle layer of
the eye between the retina and sclera, can result in decreasing vision
or even blindness.

According to a senior market research analyst at Technavio, “Behcet’s
syndrome tends to develop more in young adults who are in their 20s and
30s of all genders and races, however, it can occur in all ages. It is
most prevalent in Turkey, while in Middle Eastern countries, males are
more affected than females. However, in the US, Japan, South Korea and
other countries it occurs more in females. The prevalence of the
syndrome is increasing throughout the world due to better disease
recognition and reporting of cases
.

Behcet’s syndrome: Segmentation analysis

This pipeline analysis report segments the Behcet’s syndrome market
based on therapies employed (monotherapy), RoA (oral, parenteral and
subcutaneous), therapeutic modality (fusion protein, monoclonal
antibody, small molecule, and recombinant protein), targets (interleukin
1 beta, phosphodiesterase (PDE) 4, regulatory t-lymphocyte, t-cell, and
tumor necrosis factor alpha), MoA (interleukin 1 beta inhibitors, PDE 4
inhibitors, regulatory t-lymphocyte stimulants, t-cell activation
inhibitors, and tumor necrosis factor alpha inhibitors), geographical
segmentation (France, Korea, Turkey and US) and recruitment status
(recruiting, and active, not recruiting). It provides an in-depth
analysis of the prominent factors influencing the market, including
drivers, opportunities, trends, and industry-specific challenges.

In the current pipeline, more than 33% of the molecules that are being
investigated based on therapeutic modality, for the treatment of
Behcet’s syndrome are fusion protein.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com